The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP

Haiju HE; Yun LI; Hong TIAN; Xiaoyan XU; Jian SU; Xinxin GE; Depei WU; Ziqiang YU; Jie YIN

Return

The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP

VernacularTitle:奥妥珠单抗、糖皮质激素为基础的联合方案治疗复发性免疫性血栓性血小板减少性紫癜4例
Author: Haiju HE ¹ ; Yun LI ¹ ; Hong TIAN ¹ ; Xiaoyan XU ¹ ; Jian SU ¹ ; Xinxin GE ¹ ; Depei WU ¹ ; Ziqiang YU ¹ ; Jie YIN ¹
Author Information

1. 苏州大学附属第一医院血液内科，江苏省血液研究所，国家血液系统疾病临床医学研究中心，国家卫生健康委员会血栓与止血重点实验室，血液学协同创新中心，苏州　215006
Publication Type:Journal Article
Keywords: Immune thrombotic thrombocytopenic purpura; Relapse; Obinutuzumab; Clinical remission
From: Chinese Journal of Hematology 2025;46(1):70-74
CountryChina
Language:Chinese
Abstract: Objective:To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura (iTTP).Methods:This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment.Results:All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib. Three patients exhibited additional autoantibodies. Following the combined therapy, all patients achieved clinical remission, with ADAMTS13 activity returning to normal levels and inhibitors testing negative. During a median follow-up period of 11 months (range: 3–17 months), all patients maintained sustained remission. No severe adverse events were reported during treatment or follow-up.Conclusion:The combination of obinutuzumab and glucocorticoid-based therapy is effective and safe for treating relapsed iTTP.